Group 1 - The A-share market saw a collective rise in innovative drug concept stocks on January 7, with notable gains including a 20% increase for Beibete-U and over 17% for Yinos. [1] - Other significant performers included Chengdu XianDao with a 13% rise, and Panlong Pharmaceutical reaching a 10% increase. [1] - Additional stocks such as Yangguang Nuohuo and Zhaoyan New Drug also experienced gains exceeding 9% and 7% respectively. [1] Group 2 - The table lists various stocks with their respective codes, showing percentage increases, total market capitalization, and year-to-date performance. [2] - Beibete-U (688759) had a market cap of 18.6 billion with a year-to-date increase of 42.46%. [2] - Yinos (688710) reported a market cap of 7.611 billion and a year-to-date increase of 22.29%. [2] - Chengdu XianDao (688222) had a market cap of 12.2 billion and a year-to-date increase of 29.59%. [2] - Other stocks listed include Panlong Pharmaceutical (002864) with a market cap of 3.706 billion and a year-to-date increase of 13.07%, and Yangguang Nuohuo (688621) with a market cap of 8.188 billion and a year-to-date increase of 17.63%. [2]

Group 1 - The A-share market saw a collective rise in innovative drug concept stocks, with notable gains including a 20% limit up for Beibetter-U and over 17% increase for Yinos [1] - Other significant performers included Chengdu XianDao with over 13% rise, and Panlong Pharmaceutical with a 10% limit up [1] - Additional stocks such as Sunshine Nuohuo and Zhaoyan New Drug also experienced increases of over 9% and 7% respectively [1] Group 2 - The table lists various stocks with their respective price changes, total market capitalization, and year-to-date performance, highlighting Beibetter-U's market cap at 18.6 billion and a year-to-date increase of 42.46% [2] - Yinos has a market cap of 7.611 billion with a year-to-date increase of 22.29%, while Chengdu XianDao's market cap is 12.2 billion with a 29.59% increase [2] - Other notable stocks include Panlong Pharmaceutical with a market cap of 3.706 billion and a 13.07% year-to-date increase, and Sunshine Nuohuo with a market cap of 8.188 billion and a 17.63% increase [2]

Core Viewpoint - Yifang Biopharma has submitted an application for H-share issuance and listing on the Hong Kong Stock Exchange, focusing on its innovative drug pipeline and ongoing R&D investments [2][4]. Group 1: Financial Performance - In the first three quarters of 2025, the company reported revenue of 30.89 million yuan and a net loss of 181 million yuan, with R&D expenses reaching 190 million yuan [2]. - Since its IPO on the Sci-Tech Innovation Board in 2022, Yifang Biopharma has accumulated losses exceeding 1.189 billion yuan, indicating a heavy reliance on R&D funding [2]. Group 2: Product Pipeline - The company has two commercialized drugs, BPI-D0316 and D-1553, which are included in the national medical insurance directory, generating revenue through external licensing [2]. - Yifang Biopharma is developing core drugs D-2570 and D-0502, with D-2570 targeting conditions like psoriasis and ulcerative colitis, and potential future applications in other diseases [3]. Group 3: Market Dynamics - The price of BPI-D0316 significantly decreased after being included in the medical insurance directory, dropping from approximately 6000 yuan to between 2800 and 2862 yuan, a reduction of 52%-53%, impacting the company's revenue expectations [3]. - The market for psoriasis is expected to grow, indicating potential for future revenue despite current pricing pressures [3]. Group 4: Fundraising Purpose - The funds raised from the Hong Kong listing will be allocated to the clinical development of core products D-2570 and D-0502 to accelerate their R&D processes [4].

Core Viewpoint - Yifang Biopharma has submitted an application for H-share listing on the Hong Kong Stock Exchange, focusing on innovative targeted drugs for major diseases such as cancer and autoimmune diseases [1] Group 1: Company Overview - Yifang Biopharma specializes in the development of innovative targeted drugs, with a product pipeline that includes two marketed products and several candidates in various stages of clinical development [1] - The company's marketed products, Bafetinib and Gsorese, are included in the National Medical Insurance Drug List in China, generating revenue through external licensing [1][2] - As of the first nine months of 2025, the company reported revenue of 30.89 million yuan and a net loss attributable to shareholders of 181 million yuan, with R&D expenses amounting to 190 million yuan [1] Group 2: R&D Focus and Market Potential - Yifang Biopharma is heavily investing in R&D, particularly in new drugs such as D-2570 for psoriasis and D-0502 for breast cancer, while still in the "burning cash" phase [2] - The number of psoriasis patients in China is projected to reach 6.1 million by 2035, with the global psoriasis drug market expected to grow from $23.9 billion in 2024 to $47 billion by 2035 [2] - The company plans to initiate additional clinical trials for D-2570 targeting PsA, SLE, and vitiligo, indicating a broadening of its therapeutic focus [2] Group 3: Pricing and Market Competition - Bafetinib was included in the National Medical Insurance Directory in 2023, leading to a significant price reduction from approximately 6,000 yuan to about 2,800-2,862 yuan per box, a decrease of 52%-53% [3] - The inclusion of innovative drugs in the National Medical Insurance Directory typically results in increased market competition and reduced profit expectations for pharmaceutical companies [3] - Yifang Biopharma faces challenges with its marketed products due to price pressures and intense competition, while over half of the funds raised from its A-share IPO have already been consumed [3][4] Group 4: Financial Performance - Yifang Biopharma's IPO in July 2022 raised approximately 2.084 billion yuan, with a share price of 18.12 yuan [4] - The company has reported cumulative net losses exceeding 1.189 billion yuan from 2022 to September 2025, indicating ongoing financial challenges [4]

Investment Rating - The report maintains an "Outperform" rating for the following A-share targets: Jiangsu Heng Rui Medicine, Sichuan Kelun Pharmaceutical, Huadong Medicine, Jiangsu Nhwa Pharmaceutical, Xiamen Amoytop Biotech, Zhejiang Jingxin Pharmaceutical, Innovent Biologics, WuXi AppTec, Hangzhou Tigermed Consulting, Lepu Medical, MicroPort EP MedTech [5][36][8] - The report also maintains an "Outperform" rating for the following H-share targets: Hansoh Pharmaceutical Group, 3SBio, PATEO Biotech, Akeso, and related targets: Innovent Biologics, WuXi AppTec [8][36] Core Insights - The report continues to recommend the innovative drug and device industry and its supply chains, indicating a positive outlook for this sector [1][36] - In December 2025, the pharmaceutical sector underperformed the market, with the SW Pharmaceutical and Biological index falling by 4.1%, while the SHCOMP rose by 2.1%, ranking 26th among Shenwan primary industries [15][37] - The report highlights that the premium level of the pharmaceutical sector relative to all A-shares is currently at a normal level, with a relative premium rate of 63.2% as of the end of December 2025 [25][37] Summary by Sections A-Share Targets - The report includes a monthly portfolio of A-share targets that outperformed the pharmaceutical index, with a monthly average decline of 1.8% compared to the overall pharmaceutical index decline of 3.9% in December 2025 [11][36] - The top three stock gains in December 2025 were Luyan Pharma (+118.8%), CareRay Digital Medical Technology Co., Ltd. (+36.6%), and Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (+34.0%) [24][37] H-Share Targets - The report notes that the Hong Kong stock pharmaceutical sector also underperformed the market, with the Hang Seng Healthcare index falling by 9.5% and the Hong Kong Biological Technology index falling by 10.6% in December 2025 [26][38] U.S. Market Performance - In December 2025, the U.S. pharmaceutical sector underperformed the market, with the S&P 500 Healthcare Select Sector declining by 1.5% while the S&P 500 fell by only 0.1% [26][39]

Group 1 - A-shares opened higher today, with significant gains in innovative drug and brain-computer interface stocks, including Zhaoyan New Drug and BeiGene, which rose over 10% [1] - The innovative drug ETF Tianhong (517380) tracking the Hang Seng-Hushen-Hong Kong Innovative Drug Selected 50 Index surged over 4.8%, outperforming the Hong Kong Stock Connect Innovative Drug Index [1] - The biopharmaceutical ETF (159859) tracking the Guozhen Biopharmaceutical Index increased by over 3%, with a total scale exceeding 3.3 billion yuan and a net inflow of over 600 million yuan since September last year [1] Group 2 - The National Medical Products Administration has organized the formulation of the "Priority Approval High-end Medical Device Catalog (2025 Edition)," including medical electronic accelerators and implantable brain-computer interface medical devices [1] - Elon Musk announced that his brain-computer interface company, Neuralink, will begin large-scale production of brain-computer interface devices in 2026, transitioning to a more streamlined and nearly fully automated surgical process [1] - Analysts indicate that including implantable brain-computer interface medical devices in the priority approval category highlights policy support for related technological developments, with a broad potential market space and accelerated commercialization processes expected [1] Group 3 - McKinsey estimates that the global market size for brain-computer interface medical applications could reach $40 billion by 2030 and $145 billion by 2040, indicating significant application potential in the medical field [2] - Investors interested in the innovative drug sector can consider the innovative drug ETF Tianhong (517380) for easy access, while off-market investors may focus on linked funds [2] - The emphasis is on CXO and innovative drug mainline trends, with a recommendation to focus on the biopharmaceutical ETF (159859) that targets 30 industry leaders for higher sharpness and elasticity [2]

Group 1 - The company, Yifang Biotechnology (688382.SH), submitted an application for issuing H-shares and listing on the Hong Kong Stock Exchange on January 1, 2026 [1] - The application materials were published on the Hong Kong Stock Exchange's website and are prepared in accordance with the requirements of the Hong Kong Securities and Futures Commission and the Hong Kong Stock Exchange [1] - The published materials are draft versions and may be updated or revised, indicating that investors should not make investment decisions based solely on this information [1]

益方生物表示，该申请材料为公司按照香港证监会及香港联交所的要求编制和刊发，为草拟版本，其所 载资料可能会适时作出更新及修订，投资者不应根据其中的资料作出任何投资决定。 北京商报讯（记者 丁宁）1月4日晚间，益方生物（688382）发布公告称，公司于1月1日向香港联交所 递交了发行H股股票并在香港联交所主板挂牌上市的申请，并于同日在香港联交所网站刊登了本次发行 上市的申请资料。 ...

证券代码：688382 证券简称：益方生物 公告编号：2026-001 益方生物科技（上海）股份有限公司 关于向香港联合交易所有限公司递交 H 股发行上市 申请并刊发申请资料的公告 https://www1.hkexnews.hk/app/sehk/2026/108029/documents/sehk26010100565 _c.pdf 英文： https://www1.hkexnews.hk/app/sehk/2026/108029/documents/sehk26010100566. pdf 需要特别予以说明的是，本公告仅为境内投资者及时了解本次发行上市的 相关信息而作出。本公告以及本公司刊登于香港联交所网站的申请资料均不构 成也不得视作对任何个人或实体收购、购买或认购公司本次发行上市的 H 股的 要约或要约邀请。 公司本次发行上市尚需取得中国证券监督管理委员会、香港证监会和香港 联交所等相关政府机关、监管机构、证券交易所的备案、批准或核准，该事项 仍存在不确定性。公司将根据该事项的进展情况及时履行信息披露义务，敬请 广大投资者注意投资风险。 特此公告。 益方生物科技（上海）股份有限公司董事会 本公司董事 ...

Investment Rating - The report maintains an "Overweight" rating for the innovative pharmaceutical and medical device industry chain [4][8]. Core Viewpoints - The report continues to recommend the innovative pharmaceutical and medical device industry chain, highlighting a selection of A-share and H-share stocks with an "Overweight" rating [2][8][11]. - The performance of the pharmaceutical sector in December 2025 was weaker than the broader market, with the SW Pharmaceutical Biotechnology index declining by 4.1% compared to a 2.1% increase in the Shanghai Composite Index [18][30]. - The report notes that the premium level of the pharmaceutical sector relative to the entire A-share market is currently at a normal level, with a relative premium rate of 63.2% as of December 31, 2025 [29][32]. Summary by Sections A-Share Recommendations - The report lists the following A-share stocks with an "Overweight" rating: - 恒瑞医药 (Hengrui Medicine) - 科伦药业 (Kelun Pharmaceutical) - 华东医药 (East China Pharmaceutical) - 恩华药业 (Enhua Pharmaceutical) - 特宝生物 (Tebao Biological) - 京新药业 (Jingxin Pharmaceutical) - 益方生物 (Yifang Biological) - 药明康德 (WuXi AppTec) - 泰格医药 (Tigermed) - 乐普医疗 (Lepu Medical) - 联影医疗 (United Imaging) - 微电生理 (Microelectrophysiology) [8][9]. H-Share Recommendations - The report maintains an "Overweight" rating for the following H-share stocks: - 翰森制药 (Hansoh Pharmaceutical) - 三生制药 (3SBio) - 科伦博泰生物 (Kelun-Botai Biological) - 康方生物 (CanSino Biologics) - 映恩生物 (InnoCare Pharma) - 百济神州 (BeiGene) [11][12]. Performance Analysis - The report indicates that the 国泰海通医药 monthly portfolio outperformed the pharmaceutical index in December 2025, with an average decline of 1.8% compared to a 3.9% decline in the overall pharmaceutical index [14][15]. - The report highlights the best-performing stocks in December 2025, with 泰格医药 (Tigermed) increasing by 11.2%, 特宝生物 (Tebao Biological) by 7.5%, and 惠泰医疗 (Huitai Medical) by 3.9% [15][18].